Emerging therapies for chronic kidney disease: what is their role?

Area of Science:

• Nephrology
• Pharmacology

Background:

• Chronic kidney disease (CKD) prevalence is increasing worldwide.
• Current therapies, focusing on blood pressure and renin-angiotensin-aldosterone system blockade, offer limited efficacy against hard endpoints like end-stage renal disease.
• There is a critical need for novel therapeutic strategies to mitigate CKD progression and associated morbidity.

Purpose of the Study:

• To review emerging pharmacological strategies for slowing the progression of chronic kidney disease.
• To examine the evidence for novel agents targeting pathological hallmarks of CKD.

Main Methods:

• Review of existing literature on pharmacological interventions for CKD.
• Analysis of studies investigating agents that reduce proteinuria and delay progression in animal models.
• Evaluation of limited human trials of agents like tranilast, sulodexide, thiazolidinediones, pentoxifylline, and inhibitors of advanced glycation end-products and protein kinase C.

Main Results:

• Several agents have demonstrated potential in animal models to reduce proteinuria and slow CKD progression.
• Limited human trials have explored these agents, often using surrogate markers like proteinuria instead of hard clinical endpoints.
• Emerging therapies aim to reverse key pathological features of CKD, including inflammation, fibrosis, and atrophy.

Conclusions:

• Current treatments for CKD are insufficient to prevent progression to end-stage renal disease.
• Emerging pharmacological strategies targeting specific pathological mechanisms offer potential for more effective CKD management.
• Further robust clinical trials are necessary to validate the efficacy of these novel agents in slowing CKD progression.